Trials / Completed
CompletedNCT02210780
Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 194 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This was a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous dupilumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dupilumab | Administered via subcutaneous injection. |
| DRUG | Placebo | An inactive substance containing no medicine administered via subcutaneous injection. |
Timeline
- Start date
- 2014-08-05
- Primary completion
- 2015-09-15
- Completion
- 2015-09-15
- First posted
- 2014-08-07
- Last updated
- 2020-05-07
- Results posted
- 2020-05-07
Locations
42 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02210780. Inclusion in this directory is not an endorsement.